Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.

ABSTRACT:

Introduction

Chondrosarcoma is a malignant cartilage-forming bone tumour in which mutations in IDH1 and IDH2 frequently occur. Previous studies suggest an increased dependency on glutaminolysis in IDH1/2 mutant cells, which resulted in clinical trials with the drugs CB-839, metformin and chloroquine. In this study, the preclinical rationale for using these drugs as a treatment for chondrosarcoma was evaluated.

Methods

Expression of glutaminase was determined in 120 cartilage tumours by immunohistochemistry. Ten chondrosarcoma cell lines were treated with the metabolic compounds CB-849, metformin, phenformin (lipophilic analogue of metformin) and chloroquine.

Results

A difference in glutaminase expression levels between the different tumour grades (p = 0.001, one-way A

SUBMITTER: Peterse EFP 

PROVIDER: S-EPMC5931088 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature